Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 1:49 AM ET

Health Care Technology

Company Overview of Merge eClinical Inc.

Company Overview

Merge eClinical Inc. offers software and services to pharmaceutical, biotechnology, medical device, and contract research organizations. It offers etrials Synchronized Intelligence, an adaptive and integrated framework across the clinical trial process; and etrials Trial Intelligence that is used for managing and analyzing the progress of clinical trials via Web-based tools for collecting, managing, and analyzing real-time clinical trial information. The company also provides etrials Site Intelligence, a trial monitoring and control tool that provides access to clinical site performance, logistics, and protocol compliance; and detrials Patient Intelligence that offers modalities for capturin...

4000 Aerial Center Parkway

Suite 101

Morrisville, NC 27560

United States

Founded in 1999

100 Employees





Key Executives for Merge eClinical Inc.

Chief Information Officer and Vice President of Information Technology
Age: 54
Compensation as of Fiscal Year 2015.

Merge eClinical Inc. Key Developments

Merge eClinical Launches New Study Connect Mobile App

Merge eClinical has launched Study Connect, a new mobile app which allows eClinicalOS, or eCOS, users to perform clinical trial management functions from their iOS-based mobile devices. Seamlessly integrated with eCOS, Study Connect enables researchers to: manage randomization of subjects; coordinate dispensing and inventory management; unblind individual subjects, as circumstances warrant; stay connected with real-time customized notifications; monitor enrollment and establish milestone alerts; share top-level statistics for each study with key stakeholders using the study dashboard; expedite approval response times for critical study decisions such as patient study eligibility; and maintain security with the ability to set customized role-based permissions for individual studies. Managing study decisions and being notified of adverse events alone would make for a useful mobile EDC, but Study Connect gives eCOS users so much more. It really serves as a natural extension of their desktops and laptops.

PPCE Selects eClinicalOS Data Management Platform from Merge eClinical for Rheumatoid Arthritis Study

PPCE selected the eClinicalOS data management platform from Merge eClinical for a rheumatoid arthritis study for the pharmaceuticals company. While the number of eClinicalOS-based trials outside the U.S. has grown steadily since its launch in 2012, this study represents the first time the platform has been used to administer a trial in India. The eClinicalOS platform's design allowed the PPCE team to build and launch the study in only seven weeks. PPCE and its client were specific in the functions and features needed from a data management system. PPCE said that more stringent regulations coupled with increased cost pressure are pushing the clinical research market to adopt technology to an even greater extent than in recent years.

Verthermia Selects eClinicalOS Data Management Platform from Merge eClinical for Whole Body Hyperthermia Ovarian Cancer Treatment Trial

Verthermia Inc. has selected the Merge eClinicalOS data management platform from Merge eClinical for its clinical trial exploring the potential of whole body hyperthermia as a standalone treatment for women with Stage III or IV ovarian cancer. The U.S. Food and Drug Administration (FDA) approved the company's application to conduct the study, which began in January. The trial is the company's first cancer therapy the FDA has approved for clinical trial and it is in the safety phase of studying the treatment of late-stage solid-tumor cancers. Verthermia is actively recruiting patients as the initial study is expected to last approximately two years. The study is designed to raise a patient's core temperature to therapeutic range via the CoreHFC(TM) medical device, maintaining that temperature, detoxifying the blood and returning the patient to normal body temperature. As proven by past studies, a key advantage of regional and whole body hyperthermia is that it helps other forms of cancer treatment work better because heating cancer cells to temperatures above normal makes them easier to destroy using radiation and certain chemotherapy drugs.

Similar Private Companies By Industry

Company Name Region
SERJ Solutions, Inc. United States
Baton LLC United States
Informed Decisions, LLC United States
Patient Profiles, LLC United States
EQ2, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Merge eClinical Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at